MX366967B - Combinaciones de farmacos. - Google Patents

Combinaciones de farmacos.

Info

Publication number
MX366967B
MX366967B MX2015011147A MX2015011147A MX366967B MX 366967 B MX366967 B MX 366967B MX 2015011147 A MX2015011147 A MX 2015011147A MX 2015011147 A MX2015011147 A MX 2015011147A MX 366967 B MX366967 B MX 366967B
Authority
MX
Mexico
Prior art keywords
decitabine
derivatives
combinations
drug combinations
cancers
Prior art date
Application number
MX2015011147A
Other languages
English (en)
Other versions
MX2015011147A (es
Inventor
Mohammad Azab
Pietro Taverna
Alessia Covre
Sandra Coral
Original Assignee
Astex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Pharmaceuticals Inc filed Critical Astex Pharmaceuticals Inc
Publication of MX2015011147A publication Critical patent/MX2015011147A/es
Publication of MX366967B publication Critical patent/MX366967B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188NY-ESO
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189PRAME
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una combinación que comprende los siguientes componentes separados: (i) un compuesto de fórmula I o una sal farmacéuticamente aceptable de este: (grupo 5-azacitosina)-L-(grupo guanina) (I) en donde L es un enlazador que contiene fósforo de fórmula (II): en donde R1 y R2 son independientes H, OH, un grupo alcoxi, un grupo alcoxialcoxi, un grupo aciloxi, un grupo carbonato, un grupo carbamato o un halógeno; R3 es H, o R3, junto con el átomo de oxígeno al cual R3 está unido, forma un éter, un éster, un carbonato o un carbamato; R4 es H o R4, junto con el átomo de oxígeno al cual R4 está unido, forma un éter, un éster, un carbonato o un carbamato; y X, junto con los átomos de ox´geno a los cuales X está unido forma un fosfodiéster, un diéster de fosforotioato, un diéster de boranofosfato o un diéster de metilfosfonato; y (ii) uno o más componentes terapeúticos complementarios en donde dicho componente terapéutico complementario es un agente de activación de linfocitos T; en donde dicho compuesto de fórmula I o una sal farmacéuticamente aceptable está adaptado para ser administrable antes de dicho componente terapéutico complementario .
MX2015011147A 2013-03-01 2014-02-27 Combinaciones de farmacos. MX366967B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771525P 2013-03-01 2013-03-01
US201361887165P 2013-10-04 2013-10-04
PCT/US2014/019137 WO2014134355A1 (en) 2013-03-01 2014-02-27 Drug combinations

Publications (2)

Publication Number Publication Date
MX2015011147A MX2015011147A (es) 2016-04-28
MX366967B true MX366967B (es) 2019-07-31

Family

ID=50288308

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011147A MX366967B (es) 2013-03-01 2014-02-27 Combinaciones de farmacos.
MX2019008822A MX2019008822A (es) 2013-03-01 2015-08-27 Combinaciones de farmacos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019008822A MX2019008822A (es) 2013-03-01 2015-08-27 Combinaciones de farmacos.

Country Status (25)

Country Link
US (2) US20160015805A1 (es)
EP (2) EP3563836A1 (es)
JP (2) JP6514647B2 (es)
KR (1) KR20150125963A (es)
CN (2) CN105025884B (es)
AU (1) AU2014223348B2 (es)
CA (1) CA2902433A1 (es)
CY (1) CY1122554T1 (es)
DK (1) DK2961388T3 (es)
ES (1) ES2734023T3 (es)
HK (1) HK1219663A1 (es)
HR (1) HRP20191171T1 (es)
HU (1) HUE044430T2 (es)
IL (2) IL240894B (es)
LT (1) LT2961388T (es)
MX (2) MX366967B (es)
PH (2) PH12015501905A1 (es)
PL (1) PL2961388T3 (es)
PT (1) PT2961388T (es)
RU (2) RU2019138702A (es)
SA (1) SA515360959B1 (es)
SG (2) SG11201506727RA (es)
SI (1) SI2961388T1 (es)
WO (1) WO2014134355A1 (es)
ZA (2) ZA201506150B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
NZ747418A (en) 2014-03-12 2023-05-26 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
BR122023025321A2 (pt) 2014-05-13 2024-02-20 Medimmune Limited Uso de anticorpos anti-b7-h1 e anti-ctla-4
US10869926B2 (en) * 2014-07-15 2020-12-22 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
AU2015329070B2 (en) 2014-10-07 2018-11-22 Nec Corporation Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
WO2016061231A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
ES2805829T3 (es) 2015-03-09 2021-02-15 Cytlimic Inc Péptido derivado de GPC3, composición farmacéutica para el tratamiento o la prevención de cáncer usando el mismo, inductor de inmunidad y método para producir células presentadoras de antígeno
EP3281641B1 (en) 2015-04-07 2020-12-16 Cytlimic Inc. Adjuvant for cancer vaccines
JP6768722B2 (ja) * 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
EP3727374A4 (en) * 2017-12-21 2021-11-10 Merck Patent GmbH COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
CN108948203B (zh) * 2018-08-09 2019-06-04 南京鼓楼医院 抗pd-1单克隆抗体及其制备方法和应用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
PE20231054A1 (es) * 2020-04-24 2023-07-11 Genexine Inc Metodo para tratamiento del cancer cervicouterino

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232604T2 (de) 1992-11-04 2002-11-07 City Of Hope Duarte Antikörperkonstrukte
DK1659178T3 (da) 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US20030148973A1 (en) 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
WO2005033278A2 (en) 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
DE602005012686D1 (de) * 2004-05-26 2009-03-26 Biovaxim Ltd Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von cngen und behandlungsverfahren dafür
JP2008518902A (ja) 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク 乳癌のためのctla4抗体とアロマターゼ阻害剤の併用治療
EP1833506B1 (en) 2004-12-29 2015-08-26 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
BR112012000828A8 (pt) * 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
HUE033312T2 (en) * 2009-07-20 2017-11-28 Bristol Myers Squibb Co Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
WO2012033953A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
CN105601741A (zh) * 2011-04-15 2016-05-25 卡姆普根有限公司 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
EP2750768B1 (en) * 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
WO2014128245A1 (en) * 2013-02-21 2014-08-28 CORAL, Sandra Dna hypomethylating agents for cancer therapy

Also Published As

Publication number Publication date
US20160015805A1 (en) 2016-01-21
JP2019142911A (ja) 2019-08-29
ES2734023T3 (es) 2019-12-03
HK1219663A1 (zh) 2017-04-13
RU2019138702A (ru) 2020-01-27
PL2961388T3 (pl) 2019-10-31
PT2961388T (pt) 2019-07-11
CN105025884A (zh) 2015-11-04
MX2015011147A (es) 2016-04-28
EP2961388A1 (en) 2016-01-06
SI2961388T1 (sl) 2019-10-30
RU2015141628A3 (es) 2018-03-07
LT2961388T (lt) 2019-08-26
KR20150125963A (ko) 2015-11-10
DK2961388T3 (da) 2019-07-08
PH12015501905A1 (en) 2016-01-11
ZA201506150B (en) 2019-11-27
NZ750690A (en) 2020-09-25
JP2016510030A (ja) 2016-04-04
US20200009247A1 (en) 2020-01-09
AU2014223348B2 (en) 2018-12-13
IL240894B (en) 2020-10-29
CN110448566A (zh) 2019-11-15
NZ711757A (en) 2020-09-25
SA515360959B1 (ar) 2019-04-03
AU2014223348A1 (en) 2015-09-03
HRP20191171T1 (hr) 2019-10-04
EP3563836A1 (en) 2019-11-06
PH12019550222A1 (en) 2021-10-04
CA2902433A1 (en) 2014-09-04
RU2015141628A (ru) 2017-04-06
SG10201707135RA (en) 2017-10-30
CY1122554T1 (el) 2021-01-27
WO2014134355A1 (en) 2014-09-04
IL240894A0 (en) 2015-10-29
IL277385A (en) 2020-11-30
ZA201905426B (en) 2022-07-27
SG11201506727RA (en) 2015-09-29
MX2019008822A (es) 2019-09-26
RU2708246C2 (ru) 2019-12-05
HUE044430T2 (hu) 2019-10-28
CN105025884B (zh) 2019-08-20
JP6514647B2 (ja) 2019-05-15
EP2961388B1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
PH12019550222A1 (en) Drug combinations
CY1120421T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
PH12018501678A1 (en) Decitabine derivative formulation
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
MX2015012933A (es) Micrordenamiento para suministro de agente terapeutico y metodos de uso.
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
NZ711373A (en) Fragments of p97 and uses thereof
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
CL2015002835A1 (es) Nuevos derivados de piridina
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2014010713A (es) Activacion de procaspasa 3 mediante terapia de combinacion.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
AR094879A1 (es) Formulación oral y suspensión de un fármaco oncológico
TR201902863T4 (tr) Eri̇tropoi̇eti̇n ve seftri̇akson i̇çeren farmasöti̇k bi̇r bi̇leşi̇m ve parki̇nson hastaliği demansinin tedavi̇si̇ i̇çi̇n bi̇r i̇lacin üreti̇lmesi̇nde bunun bi̇r kullanimi.
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2018001658A (es) Agente terapeutico contra tumores.
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом

Legal Events

Date Code Title Description
FG Grant or registration